Clinical Trial Update: A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating GLPG2737 for Autosomal Dominant Polycystic Kidney Disease was terminated, with results posted on 2024-08-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• GLPG2737

Snippet

Sponsor: Galapagos NV | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-08-22